Register to receive a free Cardiac Surgery and Heart Valve Devices Market Report Suite for US synopsis and brochure
The FDA is evaluating recent reports of Getinge’s Maquet/Datascope intra-aortic balloon pump (IABP) devices shutting down while running on battery power. These devices are used on critically-ill patients in health care facilities, including during transport. An interruption in treatment can result in serious patient injury or death.
The Maquet/Datascope lABP is a cardiac assist device placed in the descending aorta, just distal to the left subclavian artery. The device is an electromechanical system used to inflate and deflate intra-aortic balloons, which provides temporary support to the heart’s left ventricle by increasing coronary perfusion and reducing left ventricular work. Getinge manufactures the following Maquet/Datascope IABP devices: Cardiosave (Hybrid and Rescue), CS300 and CS100/CS100i.
Since 2017, the FDA has received over 75 medical device reports of Maquet/Datascope IABP devices shutting down while running on battery, leading to pump stop and loss of hemodynamic support. Five of these reports described three patient deaths, although the deaths cannot be definitively attributed to the device shutting down. Other reports describe serious patient injury such as a sudden drop in blood pressure or the need for resuscitation. At least six reports indicated that there was no alarm warning before the device shutdown.
The onset of the shutdown as described in the reports ranges from immediately following disconnection of the IABP from AC power (electricity) to within the expected battery run time.
In addition to device shutdown, there are reports describing several battery issues that could lead to patient harm, such as the device not charging the battery, the battery charge indicator not working properly or not showing the correct status of the battery charge, or the battery depleting sooner than expected.
At this time, the root cause or incidence rate of these IABP devices shutting down while on batteries is not known. Although we are concerned about the device shutdown events associated with Maquet/Datascope IABPs, we recognize that these systems may be the best option for circulatory support for some patients. The FDA wants to ensure you are aware of these device failures that have been observed in patients treated with Maquet/Datascope IABPs and reported to the FDA.
The FDA recommends that health care providers and facilities should follow each device’s Operating Instructions Manual for recommendations on usage, charging, maintenance and storage of the system batteries, since battery run times and discharge cycles vary between IABP models.
In addition, the FDA recommends that users and servicers of Maquet/Datascope IABP devices should:
- – Ensure the IABP system is plugged into an AC outlet whenever possible during patient use to prevent the battery from depleting.
- – Ensure the IABP system is plugged into an AC outlet when the system is not in use. The batteries should be kept at a full charge even when the IABP is not in use.
- – When transporting patients within or between facilities, please refer to the system’s Operating Instructions Manual for recommendations for portable/battery operation. For example:
- – Prior to portable operation, the battery should be fully charged
- – Additional charged batteries should be on hand during transport, if applicable for the system
- – Ensure the batteries are properly seated in the battery compartment/charger
- – Periodically check battery run time and replace batteries as required, as recommended in each system’s Operating Instructions Manual. A reduction in run time can occur over a battery’s life for reasons such as age, storage temperature and discharge depth. Batteries should be replaced:
- – After reaching the maximum number of charge-discharge cycles
- – When the battery provides less than the minimum expected run time
- – When the labeled lifetime of the battery is reached
- – If the battery is broken, cracked, leaking or damaged
The FDA is working with the device manufacturer to better understand these device shutdown events while running on battery for Maquet/Datascope IABPs, and any contributing factors. The FDA will keep the public informed if significant new information becomes available.
For Further Information
More on the cardiac surgery and heart valve devices market in the US can be found in a series of reports published by iData entitled the US Market Report Suite for Cardiac Surgery and Heart Valve Devices. This report covers the following market segments: tissue heart valves, mechanical heart valves, annuloplasty repair devices, transcatheter mitral valve repair (TMVR) devices, transcatheter heart valve replacement (THVR) devices, on-pump coronary artery bypass (ONCAB) devices, off-pump coronary artery bypass (OPCAB) devices, endoscopic vessel harvesting (EVH) devices, anastomosis assist devices (AADs), transmyocardial revascularization (TMR) devices, ventricular assist devices (VADs), intra-aortic balloon pumps, temporary artificial heart replacement devices, extracorporeal membrane oxygenation (ECMO), remote hemodynamic monitoring, patent foramen ovale (PFO), atrial septal defect (ASD) devices, ventricular septal defect (VSD) devices and left atrial appendage (LAA) devices.
Reports provide a comprehensive analysis including units sold, procedure numbers, market value, forecasts, as well as detailed competitive market shares and analysis of major players’ success strategies in each market and segment. To find out more about cardiac surgery market data or procedure data, register online or email us at firstname.lastname@example.org for a US Market Report Suite for Cardiac Surgery and Heart Valve Devices brochure and synopsis.